Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2024-04-18 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2023年度财务决算报告 (2023 Annual Financial Settlement Report) of 美康生物科技股份有限公司, containing detailed financial statements including income statement, balance sheet, cash flow statement, and notes on financial performance for the full fiscal year 2023. It includes audited financial data with a standard unqualified audit opinion from an accounting firm. The document length is 7334 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. Therefore, this is a full Annual Report covering company activity and full financial performance for the year 2023. FY 2023
2024-04-18 Chinese
2023年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 美康生物科技股份有限公司 regarding the use and management of funds raised through a specific stock issuance in 2023. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, discusses the amount of funds raised, their allocation, usage, and management, and includes detailed tables and explanations about the investment projects funded by these raised funds. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2023. This type of report corresponds to a Capital/Financing Update, as it focuses on fundraising activities and the use of those funds rather than a full annual report or earnings release. It is not an announcement of a report publication but the report itself, given its length and detailed content. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-04-18 Chinese
关于续聘2024年度会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of the auditing firm for the fiscal year 2024. It details the qualifications, past performance, and independence of the auditor, as well as the approval process by the board and audit committee. It does not contain any financial statements or audit reports themselves, but rather informs shareholders and the public about the intention to continue the auditor engagement subject to shareholder approval. The document length is 4114 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement related to audit matters but not the audit report itself.
2024-04-18 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司2023年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2023 of Meikang Biotechnology Co., Ltd., with verification opinions from Zhongtian Guofu Securities Co., Ltd., the sponsoring institution. It discusses the internal control evaluation scope, standards, and conclusions, including financial and non-financial internal control defects, and the sponsoring institution's verification opinion. The document is a detailed report on internal control evaluation rather than a full annual report or audit report. It is not a brief announcement or certification but contains substantive evaluation content. This fits the definition of an Audit Report / Information (AR), which includes audit reports and applied accounting principles and internal control evaluations, excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2023
2024-04-18 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "美康生物科技股份有限公司 2023 年年度报告全文" which translates to "Medical System Biotechnology Co., Ltd. 2023 Annual Report Full Text." It contains detailed sections including company overview, financial data for the year 2023, management discussion and analysis, governance, environmental and social responsibility, shareholding changes, bond information, and full financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes signatures from company officers and auditors, detailed financial metrics, and extensive narrative on industry conditions and company strategy. The presence of full financial data and management analysis confirms this is the official annual report for the fiscal year 2023. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-18 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司向特定对象发行股票之保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "保荐总结报告书" (Sponsorship Summary Report) issued by 中天国富证券有限公司 regarding 美康生物科技股份有限公司's specific stock issuance to designated investors. It details the sponsorship and continuous supervision activities related to a specific stock issuance project, including due diligence, compliance with regulatory requirements, and ongoing monitoring of the use of raised funds. The document references regulatory frameworks such as the China Securities Regulatory Commission (CSRC) rules and Shenzhen Stock Exchange listing rules. It includes detailed descriptions of the sponsorship institution, representatives, and their responsibilities, as well as evaluations of the issuer's compliance and information disclosure. The document length is 4270 characters, which is relatively short but contains substantive content rather than just an announcement or a certification. It is not a general annual report, earnings release, or proxy statement. It is a specialized report related to the sponsorship and supervision of a specific capital raising event (private placement). This fits best under the category of Capital/Financing Update (CAP), as it relates to the issuance of shares to specific investors and the associated sponsorship and supervision activities. Therefore, the document is classified as a Capital/Financing Update (CAP).
2024-04-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.